| Inhibrx is a clinical-stage biotechnology company with a pipeline of biologic therapeutic candidates, developed using its protein engineering expertise and proprietary single domain antibody, or sdAb, platform. Co.'s sdAb platform allows it to pursue validated targets with clinical promise, but where other antibody and biologic based approaches have failed. Co.'s existing pipeline is focused on oncology and orphan diseases. Co. has four programs in ongoing clinical trials. Three of these programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. Co.'s pipelines include: INBRX-10, INBRX-109, INBRX-106, and INBRX-105. The INBX average annual return since 2020 is shown above.
The Average Annual Return on the INBX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether INBX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the INBX average annual return calculation with any dividends reinvested as applicable (on ex-dates).